Clinical Trial Update: Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

A Phase 2 trial of capmatinib (INC280), a cMET inhibitor, in EGFR wild-type advanced non-small cell lung cancer in Chinese patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (capmatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung Cancer | Phase 2 | Status: WITHDRAWN